Hisecco announced that its subsidiary, Liaoning Hiscus Pharmaceuticals, recently received a “Notice of Acceptance” from the State Drug Administration, and its self-developed innovative drug HSK46575 tablets were accepted for clinical trial of the new “combination with olaparib tablets or combination with docetaxel and prednisone tablets for prostate cancer treatment”. This drug is a class 1 chemical. It was approved for clinical trials for “prostate cancer” indications in December 2024, and phase I clinical research is ongoing. However, the risk of developing innovative drugs is high, and the company will disclose further progress.

Hisecco announced that its subsidiary, Liaoning Hiscus Pharmaceuticals, recently received a “Notice of Acceptance” from the State Drug Administration, and its self-developed innovative drug HSK46575 tablets were accepted for clinical trial of the new “combination with olaparib tablets or combination with docetaxel and prednisone tablets for prostate cancer treatment”. This drug is a class 1 chemical. It was approved for clinical trials for “prostate cancer” indications in December 2024, and phase I clinical research is ongoing. However, the risk of developing innovative drugs is high, and the company will disclose further progress.